-
Biogen’s Alzheimer’s drug to receive further review
–
In late January, Biogen announced that the Food and Drug Administration moved the Prescription Drug User Fee Act (PDUFA) action date for its […]
-
What’s next for embattled Alzheimer’s drug aducanamab?
–
At a J.P. Morgan Healthcare panel on January 11, representatives for Biogen cited Eli Lilly’s positive Phase 2 study of Alzheimer’s drug donanemab […]
-
Positive Phase 2 results for Alzheimer’s drug donanemab
–
On January 10, pharmaceutical giant Eli Lilly announced positive results in a Phase 2 trial of donanemab, a monoclonal antibody targeting the amyloid-β […]
-
Discovery Timeline: Neurological effects of COVID-19
–
The dizzying amount of information about COVID-19 released every day makes it difficult to keep track of the latest findings. Understanding how and […]